Date | Price Target | Rating | Analyst |
---|---|---|---|
9/18/2024 | $55.00 | Buy | Chardan Capital Markets |
7/26/2024 | $35.00 | Overweight | Morgan Stanley |
2/15/2024 | $50.00 | Buy | Canaccord Genuity |
8-K - CervoMed Inc. (0001053691) (Filer)
S-8 - CervoMed Inc. (0001053691) (Filer)
424B3 - CervoMed Inc. (0001053691) (Filer)
Chardan Capital Markets initiated coverage of CervoMed with a rating of Buy and set a new price target of $55.00
Morgan Stanley initiated coverage of CervoMed with a rating of Overweight and set a new price target of $35.00
Canaccord Genuity initiated coverage of CervoMed with a rating of Buy and set a new price target of $50.00
BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's management will participate in the following investor conferences during the month of September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Friday, September 6, 2024Time: 1:50 PM ETWebcast Link: click here H.C. Wainwright 26th Annual Global Investment ConferenceFormat: Corporate PresentationDate: Wednesday, September 11, 2024Time: 8:30 AM ETWebcast Link: click here The webcast of these presentations will be accessible in the Investor section of the C
- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in June 2024; topline data expected in December 2024 - - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod's potential for patients with early-stage DLB – - Completed private placement for up to $149.4 million of potential proceeds with leading institutional healthcare investors in April 2024 – - Added to the Russell 2000® and Russell 3000® Indexes effective July 1, 2024, as part of the 2024 Russell U.S. Indexes annual reconstitution -
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings. Presentation Details Format: Fireside ChatDate: Tuesday, August 13, 2024Time: 12:30 PM ETWebcast Link: https://wsw.com/webcast/canaccord98/crvo/2485318 The webcast of the fireside chat will be accessible in the Investors section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMe
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $65 price target.
Brookline Capital analyst Tyler Bussian initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target of $63.
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its expected addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective when the U.S. equity markets open on Monday, July 1, 2024, according to the final preliminary list of 2024 additions posted on the FTSE Russell website on June 21st 2024.
SC 13G - CervoMed Inc. (0001053691) (Subject)
SC 13G/A - CervoMed Inc. (0001053691) (Subject)
SC 13D/A - CervoMed Inc. (0001053691) (Subject)